Icon

PENBRITIN-S (nda050072)- (EQ 125MG BASE/VIAL,EQ 250MG BASE/VIAL,EQ 500MG BASE/VIAL,EQ 1GM BASE/VIAL,EQ 2GM BASE/VIAL,EQ 4GM BASE/VIAL)

AMPICILLIN SODIUM WYETH AYERST
EQ 125MG BASE/VIAL,EQ 250MG BASE/VIAL,EQ 500MG BASE/VIAL,EQ 1GM BASE/VIAL,EQ 2GM BASE/VIAL,EQ 4GM BASE/VIAL
No No
Expired Expired
None None
None No
PENBRITIN-S for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: *Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. *Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria (Listeria monocytogenes, N. meningitidis). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. *Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. *Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. *Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy.
8 0 6
Total Other Developers None
Drugs with Suitability Yes
EQ 125MG BASE/VIAL ** ** - - -
EQ 250MG BASE/VIAL ** ** - - -
EQ 500MG BASE/VIAL ** ** - - -
EQ 1GM BASE/VIAL ** ** - - -
EQ 2GM BASE/VIAL ** ** - - 7
EQ 4GM BASE/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
No 6
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** ****** **** *********** **************** **, ***********, ***** *-****, ******* (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***
****** ***** ****** ******* ********* ****** ******* *********** ****-***, **.**.***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ***** ****** ******* ***** *** ******* ******* *********** ** **: *** ** ***, *** ** ***, *** ** ***, *** ** ***, *****, ***, **** **: *-*/*, *-* & *-*, ********* *******, ********* ******, ************, ********* ******, ***** (***) ***
****** ****** ****** *** ****** ********* ******* ******* *********** ***, *.*.*.*., *********, ********, ******* ******, ***** (***) ***
****** ************ ******* ***** *.*.*. *********** *** **** ******** ********** **, *******, *****, ***** (***) ***
****** ************ ******* ************ *********** ******* ******* *********** **** ****** ********, ***/* & ***/**, *************, ***********, ************ ****,, *********, ********* ******, ***** (***) ***
****** ******** *** *** *** ******** ********** ******** ******** ********* *********** *** ********** *, *******, ****** *****, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.